Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Phenelzine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA known ✓ | P21397 | 1/20 | 0.68 |
| ▸ | MAOB known ✓ | P27338 | 1/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.83 |
| ▸ | LMNA | P02545 | 3/20 | 0.83 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.83 |
| ▸ | GAA | P10253 | 2/20 | 0.83 |
| ▸ | MAPT | P10636 | 2/20 | 0.83 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.83 |
| ▸ | BLM | P54132 | 1/20 | 0.83 |
| ▸ | GFER | P55789 | 1/20 | 0.83 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.83 |
| ▸ | KDM1A | O60341 | 2/20 | 0.68 |
| ▸ | NPC1 | O15118 | 2/20 | 0.68 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.68 |
| ▸ | HTR1A | P08908 | 1/20 | 0.68 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.68 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.68 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.68 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.68 |
| ▸ | IDO1 | P14902 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phenelzine SCHEMBL3243562 | 0.91 | LMNA (1.00) | ALDH1A1LMNACYP3A4GAAMAPT | |
| Phenelzine SCHEMBL5072466 | 0.91 | LMNA (1.00) | ALDH1A1LMNACYP3A4GAAMAPT | |
| Phenelzine SCHEMBL40652 | 0.91 | LMNA (1.00) | ALDH1A1LMNACYP3A4GAAMAPT | |
| Phenelzine SCHEMBL27517877 | 0.89 | LMNA (0.96) | ALDH1A1LMNACYP3A4GAAMAPT | |
| Phenelzine SCHEMBL27494767 | 0.83 | ALDH1A1 (0.77) | ALDH1A1LMNACYP3A4GAAMAPT | |
| Phenelzine SCHEMBL3602263 | 0.82 | LMNA (0.91) | ALDH1A1LMNACYP3A4GAAMAPT | |
| Phenelzine SCHEMBL3644150 | 0.82 | LMNA (1.00) | ALDH1A1LMNACYP3A4GAAMAPT | |
| Phenelzine SCHEMBL34335 | 0.82 | LMNA (1.00) | ALDH1A1LMNACYP3A4GAAMAPT | |
| Phenelzine SCHEMBL6064850 | 0.80 | LMNA (0.95) | ALDH1A1LMNACYP3A4GAAMAPT | |
| Phenelzine SCHEMBL2786042 | 0.80 | CYP3A4 (0.95) | ALDH1A1LMNACYP3A4GAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1558231-A2 | DOSAGE ESCALATION AND DIVIDED DAILY DOSE OF ANTI-DEPRESSANTS TO TREAT NEUROLOGICAL DISORDERS | Cypress Bioscience, Inc. (US) | 2005-08-03 | — | — | EP | disclosed |
| US-20040106681-A1 | Dosage escalation and divided daily dose of anti-depressants to treat neurological disorders | CYPRESS BIOSCIENCE, INC. | 2004-06-03 | — | — | US | disclosed |
| WO-2004030633-A2 | DOSAGE ESCALATION AND DIVIDED DAILY DOSE OF ANTI-DEPRESSANTS TO TREAT NEUROLOGICAL DISORDERS | CYPRESS BIOSCIENCE, INC. (US) | 2004-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106681-A1 | Dosage escalation and divided daily dose of anti-depressants to treat neurological disorders | GABRE, CYP2D6, DDO | MAOA 32/4885MAOB 84/4885ALDH1A1 481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.